Priya Tomos*
Idiopathic Pulmonary Fibrosis (IPF) is a progressive and debilitating lung disorder of unknown origin, posing significant diagnostic challenges. The role of biomarkers in understanding and managing this condition is pivotal. This literature review explores the landscape of molecular and genetic biomarkers in the context of IPF. It delves into the recent advances in the field, emphasizing the potential of these biomarkers in early diagnosis, disease progression monitoring and therapeutic advancements. The review underscores the significance of biomarkers in unraveling the intricate pathogenesis of IPF and in paving the way for more personalized and effective approaches to patient care.
分享此文章